Introduction The aim of this study was to perform a systematic review of the literature to evaluate the accuracy of FDG-PET in staging and restaging of cutaneous melanoma. Methods Systematic methods were used to identify, select, and evaluate the methodologic quality of the studies as well as to summarize the overall findings of sensitivity and specificity. The search strategy consisted of identifying studies published between 2000 and 2006. Inclusion criteria were studies that evaluated the diagnostic performance of FDG-PET in staging/ restaging of cutaneous melanoma. The results were compared and pooled with a meta-analysis published previously that included studies published until 1999. The meta-analysis included 95% confidence intervals (CI) of sensitivity, specificity, likelihood-ratio (LR), and diagnostic-odds-ratio (DOR). Results The quantitative meta-analysis included 24 studies that were analysed in two groups: eight studies were included only in the regional staging analysis (group I), 13 studies were included only in the detection of distant metastases analysis (group II), and three studies were included in both analyses. Compliance with the methodologic-quality criteria was acceptable. We analysed the results of data presented in patients, lesions, basins, lymph-nodes, areas, and scans. Regarding the performance of FDG-PET in the detection of metastases, the pooled studies presented homogeneity for the negative-LR (0.15; 95% CI, 0.10-0.22) when analyzing lesions. When analyzing scans, there was global homogeneity for specificity (0.86; 95% CI, 95% CI, and DOR (37.89; 95% CI,. The pooled studies presented heterogeneity for the other items analysed. Regarding the detection of regional metastases, when analyzing lymph-nodes there was global homogeneity for specificity (0.99; 95% CI, 0.97-0.99; P=0.101). The meta-regression evidenced that the variable that most influenced the DOR of the different studies and that can explain the heterogeneity was the year of publication; this may be related to the evolution of PET technology and an improvement of sensitivity/specificity. Conclusion FDG-PET is not useful in the evaluation of regional metastases, as it does not detect microscopic disease. However, FDG-PET could be useful in the detection of distant metastases, and could suggest its utility in the management of patients with cutaneous melanoma.
Introduction
Malignant melanoma is a very aggressive tumour because of its potential to develop metastases, but its prognosis is improved if the tumour is diagnosed and treated at an early stage. Survival depends mainly on the extent of the disease; if the disease is localised, 5-year survival is 90%, whereas if the disease has spread at the moment of the diagnosis, 5-year survival is 10% [1] .
The incidence of malignant melanoma is increasing. The American Cancer Society calculates that in the United States, approximately 62,190 new cases of melanoma will be diagnosed annually, and in 2005, around 7,800 persons living in the United States died because of melanoma [2] .
Management decisions depend on accurate staging of the disease. Furthermore, prognostic information may help tailor treatments to the individual patient. In this regard, the American Joint Committee on Cancer (AJCC) has proposed a classification system into four stages based on groups at risk [3] [4] [5] . Imaging methods such as sentinel node biopsy and positron emission tomography (PET) allow improved staging and may supply the prognostic information needed.
PET with 18 F-fluorodeoxyglucose ( 18 F-FDG) has demonstrated its utility in cancer. In malignant melanoma, 18 F-FDG PET can be used for initial staging to detect spread to regional lymph nodes and distant metastases. In addition, it can be used to confirm suspected recurrent disease and restage the disease before planning surgery with curative intent [6, 7] .
Two meta-analyses that analysed the diagnostic accuracy of 18 F-FDG PET in melanoma were published in 2000-2001 [6, 7] . Since then, PET systems have improved and increased resolution. The aim of this study was to perform a metaanalysis to estimate the diagnostic accuracy of 18 F-FDG PET in patients with cutaneous melanoma and pool the results with the meta-analysis published previously by Schwimmer et al. [7] . We included studies published from 2000 to 2006 and compared these with the results of the latter mentioned metaanalysis that included studies from 1980 to 1999 [7] , to evaluate if the diagnostic accuracy of 18 F-FDG PET has improved with the new PET scanners.
Materials and methods

Study identification
Two investigators performed a systematic search of the literature to identify relevant studies published between January 2000 and January 2006 in the MEDLINE, CANCERLIT and EMBASE databases [8] . The search strategies developed in MEDLINE can be found in Supplemental Table 1 (supplemental materials are available online only). One investigator also manually reviewed the reference lists of retrieved articles. We included only studies published in English; abstracts from recent conference proceedings were not included. Studies selected in the meta-analysis of Schwimmer et al. [7] were also included; these studies had been obtained following a literature search from 1980-1999.
Study selection
Two investigators independently evaluated for inclusion the titles, abstracts, and complete articles (if available) of 431 studies identified in the search. Disagreements were resolved by discussion with the participation of a third investigator. Reviewers were not blinded to the journal, author, institution, or date of publication. We included studies published in English that (a) evaluated 18 F-FDG PET in patients with cutaneous melanoma for detection of malignant lesions, both regional and distant metastases, (b) included at least 12 patients with cutaneous melanoma, and (c) reported primary data sufficient to allow calculation of both sensitivity and specificity for detection of malignant lesions. Those studies that did not conform completely to the aim of the meta-analysis were excluded. Also, those studies that included patients with non-cutaneous (ocular, mucous of respiratory, or digestive tract, urologic, etc.) melanoma were excluded when the data of the subgroup of patients with cutaneous melanoma could not be analysed separately from the subgroup of patients with non-cutaneous melanoma. Those studies that fulfilled these inclusion criteria were further examined to exclude duplicated studies or those that were outdated by other more recent ones when the patients presented overlapped. Abstracts from MEDLINE or from congresses were not included. Studies that did not report all the primary data sufficient to allow calculation of both sensitivity and specificity for detection of malignant lesions were included only in the analysis of the methodologic quality, and were excluded from the sensitivity (quantitative) analysis.
Seventeen eligible studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] were selected from 431 potentially relevant studies (Tables 1 and 2) .
Additionally, the 13 studies [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] selected in the metaanalysis of Schwimmer et al. [7] were also included; these studies had been obtained following a literature search from 1980-1999, as described previously.
When the 17 studies included from 2000 to 2006 were added to the 13 studies included from 1980 to 1999, we analysed the articles to exclude the duplicated ones. Of the three studies published by Wagner et al. [25, 32, 37] , we excluded two of them [32, 37] and included only the most recent one [25] . Therefore, 28 studies were finally included in the meta-analysis.
Study quality
The selection criteria were designed to identify studies that fulfilled the minimum requirements. To assign a quality score to each study, we carried out a methodologic quality assess- Mean age and range of age in years of patients included in the meta-analysis ment. Second, the grade of the evidence and the contribution to the patients' management were evaluated. Reviewers were not blinded to the study title, results, authors, institution, or journal in which the study results were published. Regarding the 13 studies included from the meta-analysis of Schwimmer et al. [7] , the quality scores of the methodologic quality assessment were obtained from the published data.
To assess the methodologic quality we modified previously developed criteria by Huebner et al. [39] , Gould et al. [40] , Delgado-Bolton et al. [41] , and Schwimmer et al. [7] (criteria applied previously in cutaneous melanoma). Quality assessment was performed in all the studies included in the metaanalysis, as the complete published article was accessed in all of them. A detailed description of the application of the methodologic quality criteria is available in the Appendix. Quality levels for each article were statistically analysed to assess the existence of correlation with differences in study results. Regarding the 13 studies included from the meta-analysis of Schwimmer et al. [7] , the quality scores of the methodologic quality assessment were obtained from the published data.
Next, two investigators independently assessed the validity, grade of the evidence, and generalizability, and contribution to the patients' management in all studies included in the metaanalysis [42, 43] . Study validity criteria analyse population selection and application of the reference test. Methodologic aspects such as the selection of the study population and the application of the reference tests were analysed [44] , and their combined assessment made it possible to assign a grade of evidence and generalizability [42] . Finally, the contribution of 18 F-FDG PET to the patient-management process according to the model described by Fryback and Thornbury was assessed [43, 44] . A detailed description of the assessment of the grade of the evidence and of the application of the model of Fryback and Thornbury are presented in the Appendix. Disagreements between the two investigators were resolved by discussion.
Data abstraction
One investigator abstracted the following data from each eligible study: number, demographic characteristics and inclusion criteria of the patients; study design; melanoma characteristics; and clinical use of the 18 F-FDG PET studies. Those patients in whom the 18 F-FDG PET result was not confirmed were not included in the meta-analysis. Subgroup analysis was performed on a patient-basis, according to the clinical use of 18 F-FDG PET. Based on these aspects, two types of studies were differentiated; in some, 18 F-FDG PET was performed for regional staging of the cutaneous melanoma (group I); whereas, in others (group II), 18 F-FDG PET was performed for detection of distant metastases. Some studies presented patients of both categories, which were analysed in their corresponding group (group I or group II, never simultaneously in both). The studies included in the meta-analysis are presented in Table 1 (group I, regional staging) and Table 2 (group II, distant metastases detection).
To calculate sensitivity and specificity, true-positive (TP) was considered when 18 F-FDG PET suggested the location of a malignant lesion (either a regional lymph node or a distant metastasis) and was subsequently confirmed, whereas falsepositive (FP) was considered when this location was not confirmed. The sites suggested by 18 F-FDG PET were confirmed by histopathologic analysis of tissue obtained by biopsy or surgery, considered as the gold standard; however, imaging procedures or clinical follow-up were accepted if no histopathologic proof could be obtained. True-negative (TN) was considered when follow-up confirmed the absence of malignant lesions on the 18 F-FDG PET scan either in the regional analysis (group I) or in the whole-body analysis (group II), even if other lesions (non-related with the objective of the study) were detected. It was considered false-negative (FN) if regional lesions (in group I) or distant metastases (in group II) were identified subsequently to negative 18 F-FDG PET.
Statistical analysis
To evaluate agreement between investigators for the assessment of the grade of the evidence and change-in-management information, the weighted kappa (κ) index, considering a discordant ordinal weight, was calculated.
We estimated the 95% exact confidence intervals (CI) of sensitivity and specificity for the individual studies, weighted by the sample size, in group I and group II studies. The positive and negative likelihood ratios (LR) were calculated to assess changes in pretest probability induced by the diagnostic test result.
The global LR and diagnostic odds ratio (DOR) were obtained by the method of DerSimonian Laird (random effects model). The variability between the included studies may be due to different thresholds used, explicitly or not, to define positive and negative results of the diagnostic test. To assess this variability, a receiver operating characteristic (ROC) plane was developed with the estimates of sensitivity and specificity of the included studies. If a threshold effect is present, the plotted studies will evidence a curved pattern. The threshold effect was also studied with the Spearman correlation; if there is a threshold effect there is an inverse correlation between sensitivity and specificity. Homogeneity of the LR and the DOR was compared with the Cochran's Q test, weighted by the inverse of the variances.
To characterize the performance of a diagnostic test based on the results of multiple studies, we developed summary receiver operating characteristic (ROC) curves as described by Moses et al. [45] . The estimates of sensitivity and specificity from the included studies were combined to construct the summary ROC curve, which illustrates the trade-off between sensitivity and specificity as the threshold for defining a positive test is changed. A detailed explanation on the summary ROC curve is available in the Appendix.
To assess the sources of heterogeneity in the studies, the method of Moses-Shapiro-Littenberg can be applied adding covariables to the model [meta-regression]. The exponential transformation of the estimated coefficients of each covariable can be interpreted as the relative DOR (RDOR) of that covariable, and it indicates a change in the diagnostic performance of the test in the study due to the increase of one unit of the corresponding covariable.
Statistical analysis was performed with Meta-Disc version 1.4 program [46] .
Results
Study identification and eligibility
Our search identified 431 potentially relevant articles published in MEDLINE from 2000 to 2006 (Supplemental Table 1 in the Appendix). There were 17 eligible studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] that met all inclusion and exclusion criteria, except one of these 17 studies that did not report primary data sufficient to allow calculation of both sensitivity and specificity for detection of malignant lesions and was not included in the sensitivity or quantitative analysis [20] . These 17 studies were included in the analysis of the methodologic quality. Therefore, 17 studies were included in the quality analysis and 16 of them were included in the quantitative analysis.
Regarding the 13 studies included from the metaanalysis of Schwimmer et al. [7] , the quality scores of the methodologic quality assessment were obtained from the published data. The first two studies published by Wagner et al. [32, 37] were excluded from the quantitative analysis because they were outdated by the study published in 2005. Another three studies [30, 31, 38] were excluded from the quantitative analysis because they did not report primary data sufficient to allow calculation of both sensitivity and specificity for detection of malignant lesions.
Therefore, 24 studies were finally included in the quantitative meta-analysis and 30 were included in the methodologic quality assessment.
Study description
The 17 studies selected for the meta-analysis and published from 2000 to 2006 are summarized in Tables 1 and 2 . Nine studies [10, 11, 15, 19-22, 24, 25] analyse regional staging (group I) and are presented in Table 1 , and 11 studies [9, 10, 12-14, 16-18, 22, 23, 25] analyse the detection of distant metastases (group II) and are presented in Table 2 ; three of these studies were included in both groups [10, 22, 25] . All the studies were included in the qualitative metaanalysis. The quantitative meta-analysis was performed in 16 of the 17 studies, excluding only one study [20] ; quantitative meta-analysis was possible in seven of the nine studies included in group I [11, 15, 19, 21, 22, 24, 25] , and in ten of the 11 studies included in group II [9, 10, 12-14, 16-18, 23, 25] , one of these studies was included in the quantitative meta-analysis of both group I and group II [25] Below is a summary Number of patients studied c S-100B is a protein commonly used in the immunohistochemical diagnosis of malignant melanoma Regarding the 11 studies included from the meta-analysis of Schwimmer et al. [7] , the quality scores of the methodologic quality assessment were obtained from the published data.
Study quality
Supplemental Table 2 in the Appendix presents the scores assigned to each quality item for the 17 complete articles published from the year 2000 [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] A scores ≤50%
The remaining article presented a percentage of A scores <50% [9] , considered as low quality a Additional data regarding the results of the application of the methodologic quality criteria is available in the Appendix b The methodologic quality analysis of the 13 studies published previously to the year 2000 has been presented in the meta-analysis of Schwimmer et al. [7] This meta-analysis also analyses guideline adherence across all articles [7] Table 3 and Fig. 1 summarize the results of the methodologic quality assessment of the 30 studies included in the metaanalysis, presented with the year of publication (1993 to 2005).
Supplemental Table 3 in the Appendix presents the consensus scores of the two investigators in the assessment of study validity, grade of the evidence and contribution to patients' management for those studies included in the meta-analysis that had been published since the year 2000. The studies published previously and included in the metaanalysis of Schwimmer et al. [7] have not been included in this assessment. Non-weighted inter-rater agreement (kappa index) between the two investigators for the assessment of these aspects was 0.95 (95% CI, 0.89-1.00; p<0.01), indicating very good agreement. Below is a summary table of additional information and findings.
Assessment of study validity, grade of the evidence and contribution to patients' management Control group
No study included a control group free of the disease analysed among its patients Reference tests
All the studies used appropriate and objective reference tests: histopathologic confirmation and clinical follow-up. 18 F-FDG PET was performed and interpreted blinded to both reference tests in all the studies. However, histopathologic confirmation is a non-independent reference test, as it is based in part on imaging results with 18 F-FDG PET. Clinical follow-up information is an independent reference test that was correctly applied in all studies, except in three studies of group I, in which the reference test was only sentinel node biopsy or lymph node basin dissection. Follow-up times were too short (<12 months) in five studies. Twelve studies reported a follow-up of at least 12 months [9, 10, 12, 14, 15, 17-21, 23, 25] , the minimum required to consider the reference test as unbiased. Two studies described the range of follow-up times [10, 22] . Therefore, application of reference tests was considered adequate Study validity Assessment of the validity and quality of the research methods classified 14 studies (82.35%) in grade of evidence C [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [21] [22] [23] [24] . Grade C is considered weak evidence and includes studies with several flaws in research methods, small sample sizes, or incomplete reporting; these studies present a narrow spectrum of generalizability [42] . Two studies (11.77%) were classified as grade D [9, 20] and only one study (5.88%) was classified as grade B [25] . Additional data regarding the assessment of study validity and the grade of the evidence can be found in the Appendix Contribution to patients' management
With regard to the assessment of the contribution to patients' management according to the efficacy model described by Fryback and Thornbury [43, 44] . These 24 studies were those that reported all the primary data sufficient to allow calculation of both sensitivity and specificity for detection of malignant lesions. The remaining six studies were only included in the analysis of the methodologic quality. The quantitative analysis was performed separately for the region studied by FDG PET, separating into regional staging (group I) and detection of distant metastases (group II). Also, in each region the quantitative analysis analysed subgroups of studies that presented the same method of counting findings (patients, lesions, basins, etc). Finally, only those studies that provided all the data regarding TP, TN, FP, and FN necessary for calculation of sensitivity and specificity were included. Therefore, the quantitative analysis included 24 studies that were analysed in the following groups: eight studies were included only in the regional staging analysis (group I), 13 studies were included only in the detection of distant metastases analysis (group II), and three studies were included in both analyses (group I and group II).
Regional staging: diagnostic accuracy of 18 F-FDG PET
In group I (regional staging) data was analysed with three different methods of counting findings: patients, basins, and lymph nodes ( To assess the sources of heterogeneity in the studies, the method of Moses-Shapiro-Littenberg [45] was applied, adding covariables to the model (meta-regression). The exponential transformation of the estimated coefficients of each covariable can be interpreted as the relative DOR (RDOR) of that covariable, and it indicates a change in the diagnostic performance of the test in the study due to the increase of one unit of the corresponding covariable. Heterogeneity analysis showed that differences in study quality did not correlate with differences in study results. Both the sensitivity analysis and the meta-regression evidenced that the variables that influenced the DOR of the different studies, and that can explain the heterogeneity, were the year of publication (beta 2.37; P=0.02) adjusted by the methodologic quality (beta −0.36; P=0.10) and the grade of the evidence (beta 1.37; P=0.49).
Discussion
Discussion of the heterogeneity of the results and comparison with previous systematic reviews
The results of the systematic review and meta-analysis suggest that 18 F-FDG PET could be useful in patients with cutaneous melanoma for the detection of distant metastases. 18 F-FDG PET presents intermediate-high sensitivity and high specificity, indicating the existence of few false-positives and falsenegatives. This is important in the management of oncologic patients and suggests that more benefits may be obtained if 18 F-FDG PET is performed at an early stage of the management process when metastases are suspected. Regarding the detection of regional metastases, 18 F-FDG PET is clearly inferior to sentinel node biopsy, as it presents a low sensitivity.
The meta-regression evidenced that the variable that most influenced the DOR of the different studies and that can explain the heterogeneity was the year of publication.
The methodologic quality and the grade of the evidence had a small influence on heterogeneity. Heterogeneity analysis showed that differences in study quality did not correlate with differences in study results. One of the reasons that may explain the influence of the year on heterogeneity is the evolution of PET technology, with new equipment that provides increased resolution that improves sensitivity and specificity. Other reasons that can contribute are the improvement of the PET procedures and increased experience of the physicians that report the PET scans.
The studies included in the meta-analysis present a certain degree of heterogeneity regarding the design of the study, stage of the patients included and data analysed. To Presentation of the methodology quality of the studies combined with the year of publication. The methodology quality of the studies is presented as the percentage of adequate (%A) adherence to the methodologic quality criteria guidelines analyse the data presented in these studies, we combined like data to achieve best overall numbers when we found there was homogeneity. We analysed the results of data presented in patients, lesions, basins, lymph nodes, areas and scans. Regarding the performance of 18 F-FDG PET in the detection of metastases, the pooled studies presented homogeneity for the negative LR when analysing lesions. When analysing scans, there was global homogeneity for specificity, positive LR, DOR and the summary ROC. It also presented homogeneity for areas (although of limited value because only two studies were included). The pooled studies presented heterogeneity for the other items analysed. Regarding the performance of 18 F-FDG PET in the detection of regional metastases, there was global homogeneity for specificity (Sp) values (although the P-value is near the limit of significance) when analyzing lymph nodes. However, sensitivity presented heterogeneity. When we pooled the data for lymph nodes, we found high sensitivity and specificity. The high sensitivity obtained for lymph nodes does not correlate with the results obtained for patients and basins in regional staging, and this is probably due to the presence of several possible biases such as inclusion and confirmation bias. Regarding the inclusion bias, only four studies were pooled to analyse lymph nodes in regional staging, and two of these studies analysed only superficial or peripheral lymph nodes [26, 36] . A confirmation bias may also explain the few false-negatives, as micrometastases that were not detected by 18 F-FDG PET may have not been detected eventually if an adequate reference method was not applied (histopathology, followup). On the other hand, another confirmation bias can be due to the fact that all the hot spots detected by 18 F-FDG PET and interpreted as malignant lymph nodes cannot all be confirmed pathologically as this is often not feasible because of ethical reasons. Therefore, this confirmation bias can reduce the number of false-positives and increase the number of true-positives, increasing both sensitivity and specificity. The pooled studies presented heterogeneity for patients and basins.
Previously, two meta-analyses have been published on melanoma. Schwimmer et al. [7] included 13 studies, but pooled the results of eight of them. Mijnhout et al. [6] included 11 studies, but pooled the results of six of them. Our results are similar to those presented by Schwimmer et al. [7] regarding the detection of regional metastases (when basins are analysed) and the detection of distant metastases (when lesions and patients are analysed). However, our meta-analysis includes the eight studies analysed in this previous meta-analysis and pools the results with those presented in the studies published in the last 5 years. In our meta-analysis we included 30 studies in the methodologic quality analysis and 24 in the quantitative analysis. The other meta-analysis published by Mijnhout et al. [6] did not analyse separately like data (patients, lesions, basins, etc.) and considered the results of studies that referred to patients, scans and basins comparable. This meta-analysis presented a pooled estimate for sensitivity and specificity for the detection of distant metastases of 0.78 and 0.88, respectively. These results are not comparable with our meta-analysis due to the different methodology used, although they seem to be an average of our results in the detection of distant metastases in patients, lesions, areas and scans.
Discussion of the methodologic quality Sensitivity analysis revealed that differences in the methodological quality did not correlate with differences in study results. However, the correlation between methodological quality and study results was only performed in 24 studies [9-19, 21-29, 33-36] . In the remaining six studies, only the analysis of the methodologic quality was available [20, 30, 31, 38] or they were excluded because they were Fig. 1 Presentation of the methodology quality of the studies combined with the year of publication. The methodology quality of the studies is presented as the percentage of adequate (%A) adherence to the methodologic quality criteria guidelines outdated by a more recent study [32, 37] . The methodological quality analysis of the results evidenced an increase in the methodologic quality in the 30 studies analysed when correlated with the year of publication. Further discussion of the results of the application of the methodologic quality criteria can be found in the Appendix.
The 17 studies published from the year 2000 and included in the meta-analysis presented methodological defects in the grade of evidence analysis, concerning reference test application, sample sizes or incomplete reporting, and were thus classified as weak evidence except the study by Wagner et al. [25] that was classified as highquality evidence. Study populations were small in five studies [9, 10, 19, 20, 23] , which analysed <35 patients; the remaining 12 studies analysed >35 patients. The application of the reference tests is an important methodological aspect. The availability of two reference tests, one dependent on the image, the histopathologic confirmation, and another independent one, the clinical follow-up, makes it possible to evaluate the presence of verification bias due to the incorporation of the imaging information into the final diagnosis [44] . The clinical follow-up is performed with times that are too short (<12 months) in six studies [10, 11, 13, 16, 24, 25] and with diagnostic procedures whose diagnostic accuracy is less than 100%, so that it never reaches the certainty level of the histopathologic confirmation [44] . However, histopathologic confirmation is not justified in patients in whom no alterations are observed in the 18 F-FDG PET. Moreover, in patients in whom many lesions are detected, histopathologic confirmation of all the hot spots detected by 18 F-FDG PET is not justified.
Discussion of the possible bias
Regarding the language of the studies included in the metaanalysis, only studies published in English were included. Because of this, therefore, we can not exclude the so-called Tower of Babel bias described by Grégoire et al. [47] , which can reduce the accuracy and increase systematic errors [48] . This bias refers to the fact that investigators Fig. 2 Specificity of the detection of regional metastases considering the four studies that analysed lymph nodes and estimation of the pooled effect. There was global homogeneity in the specificity, indicating there are few false-positives Fig. 3 Negative LR of the detection of distant metastases considering the six studies that analysed lesions and estimation of the pooled effect.
There was global homogeneity in the negative LR, and the test will generate moderate changes in the post-test probability working in a language other than English could be sending studies with positive results to international journals. When negative or non-significant results are found, the authors could be less confident about having it published in an international journal written in English and would thus only send it to a national journal in their language. By only including studies published in English, studies with negative results could have been left out. The limitations of this meta-analysis are: the studies reviewed do not present high-quality evidence, as they analyse different patient populations; the data analysed and the objectives are varied; there are few studies and frequently small patient populations are included; and there are several methodologic imperfections such as valid reference test with follow-up times that are frequently too short, and histopathologic confirmation is not always possible. The results of the meta-analysis evidence these differences in the studies, as heterogeneity of the sensitivity and specificity was detected in most of the data analysed. Future studies must be designed and performed rigorously to supply high-quality evidence.
Discussion of the change in management data
The contribution of an imaging procedure to the management of a patient is difficult to measure since many variables and effects must be taken into account. The Fryback and Thornbury model assigns each one of these variables an efficacy level that would indicate the contributions of a particular study [43] . This model was applied to the studies published from the year 2000. The efficacy level 4, therapeutic efficacy, was reached by only three studies [10, 13, 17] , since they describe the changes in the treatments applied as a consequence of the imaging results, an important aspect in the validation of expensive procedures such as the 18 F-FDG PET. These three studies suggest that 18 F-FDG PET changed the treatments applied in 15.1% [13] , 26% [17] and 88.2% [11] of the patients analysed. No studies reached efficacy level 5 or patient outcome efficacy.
Further discussion of the results of the assessment of the change in management information is available in the Appendix. Fig. 5 Positive LR of the detection of distant metastases considering the three studies that analysed scans and estimation of the pooled effect. There was global homogeneity in the positive LR, and the test will generate moderate changes in the post-test probability Fig. 4 Specificity of the detection of distant metastases considering the three studies that analysed scans and estimation of the pooled effect. There was global homogeneity in the specificity, indicating there are few false-positives
Conclusions
The results obtained suggest that 18 F-FDG PET could be useful in patients with cutaneous melanoma for the detection of distant metastases. 18 F-FDG PET presents intermediate-high sensitivity and high specificity, indicating the existence of few false-positives and falsenegatives. This is important in the management of oncologic patients and suggests more benefits may be obtained if 18 F-FDG PET is performed in an early stage of the management process when metastases are suspected. Regarding the detection of regional metastases, 18 F-FDG PET is clearly inferior to sentinel node biopsy, as it presents a low sensitivity. The meta-regression evidenced that the variable that most influenced the DOR of the different studies and that can explain the heterogeneity was the year of publication. This may be related to the evolution of PET technology, with new equipment that provides increased resolution which improves sensitivity and specificity.
To determine the clinical utility of 18 F-FDG PET in the detection of distant metastases in cutaneous melanoma more data are needed. Methodologically rigorous studies will allow to assess properly the role of 18 F-FDG PET in these patients. In these studies, the incremental value of 18 F-FDG PET over other diagnostic tests must be demonstrated. If evidence of favourable changes in management is finally Fig. 6 DOR of the detection of distant metastases considering the three studies that analysed scans and estimation of the pooled effect. There was global homogeneity Fig. 7 Summary ROC curve of the detection of distant metastases considering the three studies that analysed scans. There was global homogeneity. It evidences the studies tend to be grouped in the top left margin, indicating global high sensitivity and specificity reported, as the preliminary data presented in this study suggest, a cost-effectiveness study could be performed. Thus, the role of 18 F-FDG PET instead of other procedures will be properly evaluated and the improvement in accuracy and the costs reduction (due to avoiding unnecessary procedures) will be analysed. Therefore, it would be possible to perform an adequate assessment of the aplicability of 18 F-FDG PET in this clinical situation, and elaborate rational recommendations for the use of 18 F-FDG PET in melanoma patients. Another aspect to be taken into account is the continuous improvement of the PET and PET/CT systems, which may improve the diagnostic performance. If this occurs, new studies will have to assess the role of 18 F-FDG PET in melanoma patients. 
